Retrospective study and outcome of 307 cats with feline infectious peritonitis treated with legally sourced veterinary compounded preparations of remdesivir and GS-441524 (2020-2022)

Samantha S Taylor*, Sally Coggins, Emi N Barker, Danièlle Gunn-Moore, Kamalan Jeevaratnam, Jacqueline M Norris, David Hughes, Emily Stacey, Laura MacFarlane, Carolyn O'Brien, Rachel Korman, Gerard McLauchlan, Xavier Salord Torres, Aimee Taylor, Jos Bongers, Laura Espada Castro, Max Foreman, James McMurrough, Bethany Thomas, Emilie RoyauxIsabel Calvo Saiz, Guido Bertoldi, Caroline Harlos, Megan Work, Cameron Prior, Stephanie Sorrell, Richard Malik, Séverine Tasker

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

Abstract / Description of output

OBJECTIVES: Feline infectious peritonitis (FIP) is a serious disease that arises due to feline coronavirus infection. The nucleoside analogues remdesivir and GS-441524 can be effective in its treatment, but most studies have used unregulated products of unknown composition. The aim of the present study was to describe the treatment of FIP using legally sourced veterinary-prescribed regulated veterinary compounded products containing known amounts of remdesivir (injectable) or GS-441524 (oral tablets).

METHODS: Cats were recruited via email advice services, product sales contacts and study publicity. Cats were excluded if they were deemed unlikely to have FIP, were not treated exclusively with the veterinary compounded products, or if there was a lack of cat and/or treatment (including response) data. Extensive cat and treatment data were collected.

RESULTS: Among the 307 cats recruited, the predominant type of FIP was most commonly abdominal effusive (49.5%) and then neurological (14.3%). Three treatment protocols were used; remdesivir alone (33.9%), remdesivir followed by GS-441524 (55.7%) and GS-441524 alone (10.4%). The median (range) initial treatment period duration and longest follow-up time point after starting treatment were 84 (1-330) days and 248 (1-814) days, respectively. The most common side effect was injection pain (in 47.8% of those given subcutaneous remdesivir). Of the 307 cats, 33 (10.8%) relapsed, 15 (45.5%) during and 18 (54.5%) after the initial treatment period. At the longest follow-up time point after completion of the initial treatment period, 84.4% of cats were alive. The cats achieving a complete response within 30 days of starting treatment were significantly more likely to be alive at the end of the initial treatment period than those cats that did not.

CONCLUSIONS AND RELEVANCE: Legally sourced remdesivir and GS-441524 products, either alone or used sequentially, were very effective in the treatment of FIP in this group of cats. Variable protocols precluded statistical comparison of treatment regimens.

Original languageEnglish
Article number1098612X231194460
Pages (from-to)1-26
Number of pages26
JournalJournal of Feline Medicine and Surgery
Issue number9
Early online date21 Sept 2023
Publication statusPublished - Sept 2023

Keywords / Materials (for Non-textual outputs)

  • Cats
  • Animals
  • Retrospective Studies
  • Feline Infectious Peritonitis/drug therapy
  • Coronavirus Infections/veterinary
  • Cat Diseases/drug therapy


Dive into the research topics of 'Retrospective study and outcome of 307 cats with feline infectious peritonitis treated with legally sourced veterinary compounded preparations of remdesivir and GS-441524 (2020-2022)'. Together they form a unique fingerprint.

Cite this